SCHEDULE: SR One Capital Discloses 6.4% Stake in Veradermics Post-IPO

SR One Capital Management and affiliated funds have reported a 6.4% beneficial ownership in Veradermics, Inc. following the company's initial public offering and conversion of preferred stock.

Summary

• SR One Capital Management, LLC and its affiliated funds (SR One Capital Fund II Aggregator, LP and AMZL, LP) collectively beneficially own 2,401,868 shares of Veradermics, Inc. Common Stock.
• This represents 6.4% of Veradermics' outstanding Common Stock, based on 37,338,731 shares outstanding as of February 5, 2026.
• The ownership was established through a combination of pre-IPO private transactions involving Series C Convertible Preferred Stock and a purchase in the recent Initial Public Offering (IPO).
• SR One Fund II Aggregator purchased 450,000 shares in the IPO at $17.00 per share and converted 11,789,672 Series C Preferred Stock (purchased for $14,999,999.69) into 1,171,121 Common Stock.
• AMZL converted 7,859,781 Series C Preferred Stock (purchased for $9,999,999.37) into 780,747 Common Stock.
• The funds for these acquisitions were sourced from the working capital of SR One Fund II Aggregator and AMZL.
• The shares were acquired for investment purposes, with the possibility of future acquisitions or dispositions depending on market conditions and company prospects.
• Reporting Persons have entered into an Investors' Rights Agreement granting certain registration rights and a lock-up agreement restricting sales for 180 days post-IPO.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investor maintaining a substantial stake post-IPO suggests continued confidence in Veradermics' long-term prospects, despite being a routine disclosure.

Positives

• A significant investment by SR One Capital Management and affiliated funds, representing 6.4% of outstanding shares, indicates confidence in Veradermics, Inc.'s long-term potential.
• The acquisition of shares for investment purposes suggests a strategic, long-term view by a prominent institutional investor.
• The Investors' Rights Agreement provides a structured mechanism for the funds to potentially monetize their investment in the future through registered offerings, offering liquidity options.

Future Outlook

The Reporting Persons acquired their shares for investment purposes and may acquire or dispose of additional shares depending on market conditions, their continuing evaluation of Veradermics' business and prospects, and other factors. They currently have no present plans for extraordinary corporate transactions, changes in management or capitalization, or other material changes to the Issuer's business or corporate structure.

Industry Context

StockSavvy.ai notes that a Schedule 13D filing indicating a significant stake by a venture capital firm like SR One Capital Management, especially post-IPO, is common in the biotechnology or life sciences sector. These firms often invest in early-stage companies, convert their preferred stock to common stock during an IPO, and maintain a substantial position. The inclusion of registration rights and lock-up agreements are standard practices designed to manage liquidity and market stability post-IPO. This filing signals SR One Capital's continued commitment to Veradermics, Inc. as it transitions to a public company.

Comparison to Industry Standards

• The 6.4% beneficial ownership by SR One Capital Management and its affiliates is a substantial stake for an institutional investor post-IPO, aligning with typical venture capital firm strategies to maintain influence and potential for future returns in their portfolio companies.
• The conversion of Series C Convertible Preferred Stock to common stock at IPO is a standard mechanism for early-stage investors to realize their equity in a public offering, similar to what was seen with Flagship Pioneering's stake in Moderna or ARCH Venture Partners' involvement in various biotech IPOs.
• The 180-day lock-up period is a standard industry practice for IPOs, designed to prevent immediate selling pressure from pre-IPO investors and insiders, comparable to lock-up agreements seen in the IPOs of companies like Ginkgo Bioworks or Recursion Pharmaceuticals.
• The Investors' Rights Agreement, granting demand and piggyback registration rights, is also a common feature in venture capital investment agreements, providing a structured pathway for investors to sell large blocks of shares in the future without disrupting the market, similar to agreements in place for investors in companies like Denali Therapeutics or BridgeBio Pharma.

Corporate Governance

Legal Proceedings

• None of the Reporting Persons have been convicted in a criminal proceeding or been a party to a civil proceeding ending in a judgment, decree, or final order related to federal or state securities laws during the past five years.

Stakeholder Impact

• Shareholders: The significant stake held by SR One Capital Management could be seen as a vote of confidence. The lock-up agreement temporarily restricts selling pressure from these large holders, while future exercise of registration rights could increase the float and potentially create selling pressure.
• Company (Veradermics): Continued backing from a major investor like SR One Capital can provide stability and strategic support. The Investors' Rights Agreement imposes obligations on the company regarding future registration statements.

Next Steps

• Expiration of the 180-day lock-up period around August 2, 2026, after which Reporting Persons may sell shares.
• Potential future requests by holders of registrable securities for the Issuer to file S-1 or S-3 registration statements, subject to the terms of the Investors' Rights Agreement.
• Possible future acquisitions or dispositions of Veradermics shares by the Reporting Persons based on market conditions and company performance.

Key Dates

Recommendation

This Schedule 13D filing primarily serves as a regulatory disclosure of a significant ownership stake by SR One Capital Management following Veradermics' IPO. It does not contain new operational or financial performance data that would warrant a 'buy' or 'sell' recommendation. The investment by SR One Capital is a positive signal, but the filing itself is a routine update on an expected event (conversion of preferred stock and IPO participation by a major pre-IPO investor). Investors should 'hold' and await further operational updates or financial results from Veradermics to make a more informed decision.

Keywords

Veradermics, SR One Capital Management, Schedule 13D, IPO, Common Stock, beneficial ownership, institutional investment, Series C Preferred Stock, registration rights, lock-up agreement